Using machine learning to design new drugs for psychiatric disorders
Machine Learning Phenotypic De Novo Drug Design
This study is working on using smart computer techniques to help create better and safer medications for mental health conditions, so patients can have more effective treatment options that really fit their needs.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Psychogenics, INC. NIH-funded |
| Lab location | 1 site (Paramus, UNITED STATES) |
| Project ID | NIH-10907841 on NIH RePORTER |
What this research studies
This research focuses on improving drug discovery for psychiatric disorders by utilizing machine learning techniques to design new compounds. It aims to address the high failure rates in developing effective treatments by creating a model that links drug structure to their effects on behavior. By leveraging a unique screening platform and a large database of compounds, the project seeks to explore new chemical spaces that have not been previously targeted. Patients may benefit from the development of more effective and safer medications tailored to their specific conditions.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with psychiatric disorders such as autism, bipolar disorder, or anxiety.
Not a fit: Patients with psychiatric disorders that do not respond to pharmacological treatments or those who are not diagnosed with any CNS-related conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of more effective and safer drugs for psychiatric disorders.
How similar studies have performed: Other research has shown promise in using machine learning for drug discovery, indicating that this approach could lead to significant advancements in treatment options.
Where this research is happening
Paramus, UNITED STATES
- Psychogenics, INC. — Paramus, United States (Active)
Researchers
- Principal investigator: Brunner, Daniela — Psychogenics, INC.
- Study coordinator: Brunner, Daniela
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.